Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject is 18 to 75 years of age at the time of screening~* Subject is planned for facial rhytidectomy~* Subject has read, understood and signed the written informed consent~* Subject is healthy, as determined by the investigator using standard pre-operative assessments to include laboratory tests and electrocardiograms~* Subject is of childbearing potential, presents with a negative serum pregnancy test, and agrees to employ adequate birth control measures for the duration of the study~* Subject is willing and able to comply with the requirements of the protocol~Exclusion Criteria:~* Subject is indicated for an abbreviated or modified face-lift procedure such as deep plane procedures, minimal undermining procedures, thread lifts, and minimal access cranial suspension~* Subject is indicated for concurrent facial surgeries during the operation (eg forehead plasty,blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.)~* Subject is indicated for additional procedures to the body during the same operation (eg liposuction, mastoplasty etc.)~* Subject has undergone a prior rhytidectomy surgery~* Subject is an active smoker, as assessed by the investigator~* Subject has a known (documented) bleeding or coagulation disorder~* Subject is being treated with anti-coagulants or with Aspirin (that was not discontinued 7 days prior to surgery)~* Subject has a vascular disorder, cardiovascular disease, and/or uncontrolled hypertension~* Subject has diabetes mellitus with glycosylated hemoglobin (HbA1c) \> 7~* Subject is receiving active treatment for a malignancy~* Subject has a connective tissue disorder~* Subject has an active or chronic skin disorder~* Subject has history of Bell's palsy~* Subject has a documented history of pathologically or pharmacologically induced immune deficiency~* Subject has received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery~* Subject has a known sensitivity to components of FS VH S/D 4 s-apr~* Subject has a known psychiatric disorder (eg, obsessive compulsive disorder, anxiety, eating disorders, etc.)~* Subject has documented healing complications following previous surgeries (eg, hypertrophic scarring)~* Subject is pregnant or lactating at the time of enrollment~* Subject has participated in another clinical study involving an investigational product/device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product/device during the course of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- FS VH S/D 4 s-apr (Type: EXPERIMENTAL): One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
- Standard of Care (SoC) (Type: NO_INTERVENTION): Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete